Valuation: Monopar Therapeutics Inc.

Market Cap 483M 432M 399M 361M 675M 45.96B 686M 4.76B 1.9B 24.06B 1.81B 1.77B 76.19B P/E 2026 *
-29x
P/E 2027 * -28.7x
Enterprise Value 364M 326M 301M 272M 509M 34.65B 517M 3.59B 1.43B 18.14B 1.37B 1.34B 57.44B EV / Sales 2026 *
-
EV / Sales 2027 * 12x
Free-Float
76.54%
Yield 2026 *
-
Yield 2027 * -
1 day-2.02%
1 week-0.92%
Current month-9.74%
1 month-10.11%
3 months-33.06%
6 months+43.48%
Current year+10.12%
1 week 69.34
Extreme 69.335
75.32
1 month 68.8
Extreme 68.805
85.49
Current year 50.07
Extreme 50.07
124.82
1 year 50.07
Extreme 50.07
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 01/12/2014
Director of Finance/CFO 54 03/03/2025
Chief Tech/Sci/R&D Officer 64 01/09/2026
Director TitleAgeSince
Director/Board Member 42 01/12/2014
Chairman 73 01/12/2014
Director/Board Member 84 01/04/2017
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/26 Exercice

Founder

25,200 0.3754%
30/9/26 Exercice

Chief Operating Officer

10,712 0.1596%
30/9/26 Exercice

Founder

23,946 0.3568%
Change 5-day change 1-year change 3-year change Capi.($)
-2.02%-0.92%-14.55%+3,026.52% 493M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-2.07%+42.73%+103.77%+88.74% 34.47B
-0.26%-2.57%+12.55%+45.18% 32.25B
+0.09%-1.62%+23.18%-10.77% 24.23B
Average -0.24%+3.77%+45.75%+449.07% 39.3B
Weighted average by Cap. +0.09%+3.59%+49.22%+164.16%

Financials

2026 *2027 *
Net sales - 28.26M 25.31M 23.35M 21.13M 39.52M 2.69B 40.15M 279M 111M 1.41B 106M 104M 4.46B
Net income -21.46M -19.23M -17.74M -16.05M -30.01M -2.04B -30.5M -212M -84.42M -1.07B -80.55M -78.84M -3.39B -26.62M -23.84M -21.99M -19.9M -37.22M -2.53B -37.82M -262M -105M -1.33B -99.89M -97.76M -4.2B
Net Debt -119M -106M -98.14M -88.81M -166M -11.31B -169M -1.17B -467M -5.92B -446M -436M -18.75B -145M -129M -119M -108M -202M -13.77B -205M -1.43B -569M -7.2B -543M -531M -22.82B
Projected Income Statement - Annual - Monopar Therapeutics Inc.
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
29/10/26 US$71.91 -2.02% 163,110
28/10/26 US$73.39 +2.16% 187,364
27/10/26 US$71.84 +1.84% 135,925
26/10/26 US$70.54 -0.16% 84,703
23/10/26 US$70.65 -2.66% 96,754
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Monopar Therapeutics Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
71.91USD
Average target price
129.92USD
Spread / Average Target
+80.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Monopar Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. MNPR Stock